cell based therapy in inflammatory liver disease the
play

Cell based therapy in inflammatory liver disease- the MERLIN trial Dr Ashnila Janmohamed Clinical research fellow in Hepatology Birmingham Rare Disease Symposium 18 May 2018 Mesenchymal stromal cells (MSC) Heterogeneous population of

0 downloads 29 Views 5,57 MB Size Report
  1. Cell based therapy in inflammatory liver disease- the MERLIN trial Dr Ashnila Janmohamed Clinical research fellow in Hepatology Birmingham Rare Disease Symposium 18 May 2018

  2. Mesenchymal stromal cells (MSC) • Heterogeneous population of precursor cells • Multiple sources of MSC Le Blanc K & Mougiakakos. Nature reviews 2012

  3. Potential applications of MSC in liver disease Forbes & Newsome. J Hep 2012

  4. MSC have a pleiotropy of action on the immune system Alfaifi M et al. J Hep 2018

  5. MERLIN programme: MEsenchymal stromal cells to Reduce Liver INflammation Pintail Orbsen UoB NHSBT UNIPD Efficacy Clinical trial CD362+ MSC Mechanism of action

  6. Immune-mediated liver disease Webb GJ et al. Annu Rev Pathol Mech Dis 2018

  7. Primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) share the same immune-pathogenesis Tregs ê MSC T cells é TH1 é • Multifactorial- TH17 é genetic and environmental factors • Complex disease pathogenesis Macrophages é Webb GJ et al. Annu Rev Pathol Mech Dis 2018

  8. Studies • Experimental Ø In vivo studies in 3 murine models: UC-MSC effect on hepatic inflammatory activity (ALT and CD45) and T cell infiltration Ø In vitro studies: UC-MSC effect on T cell proliferation and activation using tissues from patients with PSC • Clinical trial Ø Safety and efficacy of UC-MSC in patients with PSC and AIH

  9. In vivo models of inflammatory liver injury • Ovalbumin (Ova)- Bil mouse model : Transgenic mouse model of immune-mediated hepatobiliary injury • C57BL/6 mice: Carbon-tetrachloride-induced liver injury (CCL 4 ) • Chronic Mdr2 KO/FVB mouse model : Model of sclerosing cholangitis

  10. US: Unselected MSC UC- Umbilical cord Hepatic CD45 ALT Human CD362+ UC-MSC reduce inflammation in 3 mouse % area of CD45+ cells in liver I n U j n u i r e n 0 2 4 6 8 j d u M r e d d r F 2 K V B O / F V B c o n Mdr2 -/- t U r S o l U models of inflammatory livery injury C M C S D C 3 2 6 5 2 + 0 k U ** C M S C 2 5 0 k No MSC ALT level ( IU/L) 100 200 300 400 500 0 Ova bil 10 M (OT-1 & OT-2) Ova-Bil US UC MSC CD362+ UC MSC * MSC Data from V Wigneswara & M Alfaifi ALT level ( IU/L) 100000 150000 200000 50000 100 150 200 50 Control 0 0 M.O US UC MSC 250K CCL4 US UC MSC 1M CCL4 * CD362+ UC MSC 250K CD362+ UC MSC CCl 4 CD45 Heat inactivated MSC * * CD362+ UC MSC 1M

  11. Infusion of CD362+ UC-MSC reduce hepatic CD3 + , CD4 + & CD8 + T cell infiltration in the chronic model of sclerosing cholangitis * (p=0.0255) * (p=0.0426) * (p=0.0200) * (p=0.0375) * (p=0.0264) 20000 * (p=0.0255) 60000 60000 CD8 + cells /g 15000 CD4 + cells /g CD3 + cells /g 40000 40000 10000 20000 5000 20000 0 0 0 Control US-UC MSC 250k CD362+ UC-MSC 250k Control US-UC MSC 250k CD362+ UC-MSC 250k Control US-UC MSC 250k CD362+ UC-MSC 250k * p < 0·05 Data from V Vigneswara

  12. Infusion of CD362+ UC-MSC induces CD4 + CD25 + Foxp3 + Tregs ** (p=0.0021 ) ** (p=0.0044 ) CD25 high FOXP3 + cells (%) 20 15 CD3 + CD4 + 10 5 0 Control US-UC MSC 250k CD362+ UC-MSC 250k Data from V Vigneswara * p < 0·05

  13. In-vitro assessment of efficacy of UC- MSC in patients with PSC Ø Effect of UC-MSC on CD4 + and CD8 + T cell proliferation and activation T cell proliferation and activation

  14. UC-MSC suppress peripheral blood CD4 + and CD8 + T cell proliferation from patients with PSC **** **** **** **** **** **** 100 100 % CD4+ proliferation % CD8+ proliferation 80 60 50 40 20 0 0 m 1 4 6 4 6 1 4 6 4 6 m : : 1 6 5 : : 1 6 5 i 1 1 1 1 : : 2 i : : 2 t 1 1 t 1 1 S : : S 1 1 MSC:PBMC MSC:PBMC Key Stim: stimulated PBMC only **** p≤0.0001

  15. %CD4 + TNF α + expressing cells UC-MSC reduce peripheral blood CD4 + T 100 50 0 S t i m * 1 : 1 1 TNFα MSC:PBMC TNFα : 4 1 : 1 6 1 : 6 4 1 : 2 5 6 cell activation %CD4 + IFN γ + expressing cells 100 * p< 0.05 20 40 60 80 0 S t i m * 1 *p ≤ 0.05 IFN γ : 1 * MSC:PBMC 1 : 4 1 : 1 6 1 : 6 4 1 : 2 5 6 %CD4 + IL-2 + expressing cells 100 20 40 60 80 0 S t i m 1 : 1 1 MSC:PBMC : 4 IL2 1 : 1 6 1 : 6 4 1 : 2 5 6

  16. UC-MSC suppress Intrahepatic CD4 + and CD8 + T cell proliferation from patients with PSC * ** ** * 100 100 % CD8+ proliferation % CD4+ proliferation 80 80 60 60 40 40 20 20 0 0 1 4 6 4 6 1 4 6 4 6 m m : : 1 6 5 : : 1 6 5 1 1 1 1 i : : 2 : : 2 i t 1 1 t 1 1 : : S S 1 1 MSC:CD4+ T cell MSC:CD8+ T cell

  17. UC-MSC reduce intrahepatic CD4 + T cell activation from patients with PSC TNFα IFN γ IL2 * ** ** ** %CD4 + TNF α + expressing cells %CD4+IL2 expressing cells 100 * * 100 * %CD4 + IFN γ + expressing cells 50 80 80 40 60 60 30 40 40 20 20 20 10 0 0 0 1 4 6 4 6 Stim 1:1 1:4 1:16 1:64 1:256 Stim 1:1 1:4 1:16 1:64 1:256 m : : 1 6 5 1 1 : : 2 i t 1 1 : S 1 MSC:CD4+ T cell MSC:CD4+ T cell MSC:CD4+ T cell

  18. Summary of MSC actions CD4 CD3 CD8 Hepatic Tregs inflammation Reduction TNFα CD4 CD8 IFNγ CD362+ UC-MSC Proliferation and Activation Biliary epithelial cell inflammation and death

  19. MSC clinical trials in liver disease • MSC therapy has been used in a number of clinical studies to treat liver disease (n=300) • Found to be safe • Variability in efficacy • Most studies have short follow-ups so long-term efficacy data is lacking

  20. Primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) PSC • Prevalence 16.2 per 100,000 inhabitants • Affects young patients • No licensed effective therapies Williams R et al. Lancet 2018 AIH • Prevalence 16-18 cases per 100,000 inhabitants • 10-20% patients are treatment intolerant or unresponsive • Therapies limited by side-effects & limited 2 nd line options

  21. Unmet needs of patients with PSC and AIH Patients with AIH Patients with PSC • Higher mortality risk for AIH patients Mean transplant-free survival = 14.5 years • compared to matched general population Weismüller & Trivedi et al. Gastro 2017 Groenbark et al. J Hep 2014

  22. PSC Bucket trial concept AIH Common mechanistic and clinical primary end point

  23. Primary Outcome measures • Safety and Feasibility • Disease end-point Ø Change in serum ALP (PSC) and ALT (AIH) from baseline • Mechanistic end-point Ø Increase in circulating Tregs

  24. Trial design Inclusion criteria Patients with AIH Patients with PSC Patients refractory to treatment Serum ALP ≥ 1.5 ULN at Serum ALT ≥ 1.5 ULN at screening visit screening visit STAGE 1 STAGE 2 Determine: Safety at a higher dose Determine: EFFICACY and safety Safe Safe 2.5 X 10 6 cells/kg 1.0 X 10 6 cells/kg Stage 2 n=3 n=3 Safety: Assessed by dose limiting toxicity (DLT) Chief Investigator: Prof Gideon Hirschfield and adverse events Co-CI: Prof Philip Newsome

  25. Patient pathway in the trial MSC infusion Initial f/u Long term safety f/u Screening Pre-treatment Treatment Visit 1 Visit 2 Visit 3 Visit 7 Visit 8 Visit 5 Registration SD -28 SD -7 SD 0 SD 14 SD 28 SD 56 D180 D270 D360 D720 D540 End of DLT reporting Significant clinical events period (stage 1) and serious adverse events will be captured Primary efficacy outcome measures Secondary efficacy outcome measures Change in ALP (PSC)/ALT (AIH) from baseline SD= study day

  26. Clinical trial progress • Ethical and regulatory approval (MHRA) obtained- April 2017 • Substantial amendment to MHRA submitted- April 2018 • Aim to recruit 19 patients per cohort

  27. Acknowledgements Collaborators Dan Hollyman Trial Co-ordinator Prof Gideon Hirschfield & Steve Elliman Jon Smythe Darren Barton Prof Philip Newsome Martin Hoogdjuin Rebecca Storey Vasanthy Vigneswara Carla Baan Mohammed Alfaifi Debashish Roy Trial Statistician Nguyet-Thin Luu Daniel Slade Evaggelia Liaskou Christina Yap

Recommend Documents


anti inflammatory therapy with canakinumab for
Anti-Inflammatory Therapy with

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease Paul M

cell based therapy atmps manufacturing of cell based
Cell-based Therapy ATMPs Manufacturing

Translating academic research into commercial products - regulatory

acute management of sickle cell disease objectives
Acute Management of Sickle Cell

Acute Management of Sickle Cell Disease Objectives - Overview of Sickle

outline
Outline Hematopoeitic stem cells

6 th International Conference on Neonatal Stem Cell-Based Therapy in Pulmonary

developing new diagnostics and therapies to treat
DEVELOPING NEW DIAGNOSTICS AND

DEVELOPING NEW DIAGNOSTICS AND THERAPIES TO TREAT TUBERCULOSIS AND

inflammation as a target for therapy
Inflammation as A Target for Therapy

ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on

challenges of developing cell and gene therapy products
Challenges of developing Cell and Gene

Challenges of developing Cell and Gene Therapy products in Europe Dr Sven

client alert
Client Alert Stem Cell Therapy in 2009:

Client Alert Stem Cell Therapy in 2009: From Lab to Market Contact Attorneys

pediatric inflammatory
PEDIATRIC INFLAMMATORY BOWEL DISEASE

4/6/18 PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric

therapy of chronic hcv in patients with liver cirrhosis
THERAPY OF CHRONIC HCV IN PATIENTS

THERAPY OF CHRONIC HCV IN PATIENTS WITH LIVER CIRRHOSIS DIRK NIERHOFF, PD DR.

north carolina central university
North Carolina Central University

North Carolina Central University Human Nutrition Program Xiaohe Yang, MD,

sinonasal smooth muscle cell tumor haemangiopericytoma
Sinonasal smooth muscle cell tumor

03 RJR 03 2011 - 0 BT-COR.qxd:Interior 6/30/11 8:09 PM Page 131 Romanian

13th international vhl medical symposium
13th International VHL Medical

13th International VHL Medical Symposium Selected Presentation Summaries

new project i dentification of protected corals
New project I dentification of

New project I dentification of protected corals DOC1 1 0 / I NT2 0 1 0 /

do eagles make flies ready for love
Do Eagles Make Flies Ready for Love?

Do Eagles Make Flies Ready for Love? Quinn Langdon: langdonq@reed.edu

international 2018 call for projects
INTERNATIONAL 2018 CALL FOR PROJECTS

International 2018 call for projects Projects presentation INTERNATIONAL

carsten sinz nina amla jo o marques silva emmanuel zarpas
Carsten Sinz Nina Amla Joo Marques

Carsten Sinz Nina Amla Joo Marques Silva Emmanuel Zarpas Daniel Le Berre

validation of commercial tool antibodies
Validation of Commercial tool

Validation of Commercial tool Antibodies The Antibody Society Webcast series

minerva
MINERVA Project overview presentation

MId- to NEaR infrared spectroscopy for improVed medical diAgnostics MINERVA

community college first year
Community College First-Year

Developing and Assessing a Community College First-Year Experience Program

protein carbonylation
Protein carbonylation: a marker of

Protein carbonylation: a marker of oxidative stress damage ITN-TREATMENT

med edica cations tions wi with th abus use e pote tent
Med edica cations tions wi with th

Med edica cations tions wi with th Abus use e Pote tent ntial ial for